111’s (YI) Sell (D-) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of 111 (NASDAQ:YI) in a research report released on Thursday,Weiss Ratings reports.

111 Stock Performance

Shares of NASDAQ:YI opened at $4.39 on Thursday. The stock has a market capitalization of $37.93 million, a PE ratio of -5.23 and a beta of 0.42. 111 has a 1 year low of $4.14 and a 1 year high of $11.35. The firm has a fifty day moving average price of $5.23 and a 200 day moving average price of $6.79.

111 (NASDAQ:YI) last issued its quarterly earnings data on Wednesday, September 17th. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $447.51 million for the quarter.

Institutional Investors Weigh In On 111

A hedge fund recently bought a new stake in 111 stock. Deuterium Capital Management LLC purchased a new stake in 111, Inc. Sponsored ADR (NASDAQ:YI) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,000 shares of the company’s stock, valued at approximately $81,000. Deuterium Capital Management LLC owned about 0.12% of 111 as of its most recent filing with the Securities & Exchange Commission. 21.32% of the stock is owned by institutional investors and hedge funds.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.